4 results
Primary Objective:To induce clinical response (CDAI decrease from baseline * 100 points) and/or remission(CDAI <150) following 12 weeks of treatment with one of two active doses ofGSK1605786A for qualification of subjects for enrolment into a…
Primary: Safety and tolerability. Secondary: Effectiveness, quality of life, healthcare resource utilisation, work productivity.
To determine the specificity of the effects of histamine H1-receptor blockade on different cognitive functions and processes.
To assess 1) the feasibility of in vivo measurement of biomechanical properties of the vaginal wall with the use of cutometry (Cutometer MPA 580 4mm) and indentometry (Indentometer IDM 800) and 2) the biomechanical properties of the vaginal wall.